Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024Charlotte Lanièce Delaunay, Esther Kissling, Gergő Túri et al.|Vaccine|2024Cited by 24
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024Lore Merdrignac, Charlotte Lanièce Delaunay, Nuno Verdasca et al.|Influenza and Other Respiratory Viruses|2024Cited by 14
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022Charlotte Lanièce Delaunay, Iván Martínez‐Baz, Noémie Sève et al.|Eurosurveillance|2024Cited by 11
COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care NetworkCharlotte Lanièce Delaunay, Nuno Verdasca, Susana Monge et al.|Influenza and Other Respiratory Viruses|2025Cited by 10
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older EuropeansCharlotte Lanièce Delaunay, Carla López Causapé, Clara Mazagatos et al.|JAMA Network Open|2024Cited by 10